Health Canada Accepts Arcutis’ SNDS for Roflumilast Foam 0.3% for Scalp and Body PsO
Health Canada has accepted Arcutis Canada, Inc.’s Supplement to a New Drug Submission (SNDS) for roflumilast foam 0.3% for review for the topical treatment of scalp and body psoriasis in patients aged 12 and up. Roflumilast foam is a once-daily phosphodiesterase-4 (PDE4) inhibitor. The SNDS is supported by data from Arcutis’ pivotal ARRECTOR (A Randomized […]